FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2401607958> ?p ?o ?g. }

• W2401607958 abstract "The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed.The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor were affected by these treatments and to determine the importance of the 18F-FDG PET method.Twenty metastatic bone tumor cases were included. Sorafenib and anti-VEGF were added to the standard treatment in cases with widespread metastatic disease at diagnosis or after neoadjuvant chemotherapy showing less than 90% tumor necrosis in the surgical sample. Positron emission tomography (PET) imaging was performed at diagnosis, the preoperative period following neoadjuvant chemotherapy, during postoperative follow-up, and when treatment was discontinued.The primary treatment region median SUVmax level decreased from 7.35 to 2.5 in the living patients (n = 16) while there was no significant decrease in the patients who succumbed to the disease (P < 0.001). Comparison of the pre- and post-treatment metastasis region median SUVmax levels in patients with metastatic involvement showed a decrease from 2.1 to 0 in the surviving patients but only from 4.8 to 3.2 in the deceased patients (P < 0.01). Survival results indicated that 28.6% of the patients receiving classical treatment only died while all the patients receiving additional sorafenib and anti-VEGF survived.18F-PET may be a useful technique before and during the follow-up of neoadjuvant treatment in pediatric metastatic bone tumor patients. The addition of sorafenib and anti-VEGF to classical treatment has a favorable contribution to the response and therefore the survival duration." @default.
• W2401607958 created "2016-06-24" @default.
• W2401607958 creator A5001129685 @default.
• W2401607958 creator A5001261016 @default.
• W2401607958 creator A5010124076 @default.
• W2401607958 creator A5018137849 @default.
• W2401607958 creator A5020661699 @default.
• W2401607958 creator A5026613738 @default.
• W2401607958 creator A5036632418 @default.
• W2401607958 creator A5054864064 @default.
• W2401607958 creator A5070688651 @default.
• W2401607958 date "2016-03-05" @default.
• W2401607958 modified "2023-10-01" @default.
• W2401607958 title "Can Fluorine-18-Fluorodeoxyglucose PET Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Antivegf in Children Diagnosed With Metastatical Bone Sarcoma?" @default.
• W2401607958 cites W1819640751 @default.
• W2401607958 cites W1966549658 @default.
• W2401607958 cites W1977343422 @default.
• W2401607958 cites W1990067251 @default.
• W2401607958 cites W1994157912 @default.
• W2401607958 cites W2040275378 @default.
• W2401607958 cites W2044759862 @default.
• W2401607958 cites W2096719319 @default.
• W2401607958 cites W2097502459 @default.
• W2401607958 cites W2103405666 @default.
• W2401607958 cites W2103460784 @default.
• W2401607958 cites W2123745849 @default.
• W2401607958 cites W2126455122 @default.
• W2401607958 cites W2129148702 @default.
• W2401607958 cites W2140172669 @default.
• W2401607958 cites W2144530818 @default.
• W2401607958 cites W2157873228 @default.
• W2401607958 cites W2158927044 @default.
• W2401607958 cites W2162216424 @default.
• W2401607958 cites W2167348613 @default.
• W2401607958 cites W2169931212 @default.
• W2401607958 doi "https://doi.org/10.5812/ijp.4008" @default.
• W2401607958 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4904339" @default.
• W2401607958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27307968" @default.
• W2401607958 hasPublicationYear "2016" @default.
• W2401607958 type Work @default.
• W2401607958 sameAs 2401607958 @default.
• W2401607958 citedByCount "0" @default.
• W2401607958 crossrefType "journal-article" @default.
• W2401607958 hasAuthorship W2401607958A5001129685 @default.
• W2401607958 hasAuthorship W2401607958A5001261016 @default.
• W2401607958 hasAuthorship W2401607958A5010124076 @default.
• W2401607958 hasAuthorship W2401607958A5018137849 @default.
• W2401607958 hasAuthorship W2401607958A5020661699 @default.
• W2401607958 hasAuthorship W2401607958A5026613738 @default.
• W2401607958 hasAuthorship W2401607958A5036632418 @default.
• W2401607958 hasAuthorship W2401607958A5054864064 @default.
• W2401607958 hasAuthorship W2401607958A5070688651 @default.
• W2401607958 hasBestOaLocation W24016079581 @default.
• W2401607958 hasConcept C121608353 @default.
• W2401607958 hasConcept C126322002 @default.
• W2401607958 hasConcept C126838900 @default.
• W2401607958 hasConcept C141071460 @default.
• W2401607958 hasConcept C143998085 @default.
• W2401607958 hasConcept C2775842073 @default.
• W2401607958 hasConcept C2776694085 @default.
• W2401607958 hasConcept C2777783956 @default.
• W2401607958 hasConcept C2778019345 @default.
• W2401607958 hasConcept C2778292576 @default.
• W2401607958 hasConcept C2778695046 @default.
• W2401607958 hasConcept C2779013556 @default.
• W2401607958 hasConcept C2780283643 @default.
• W2401607958 hasConcept C530470458 @default.
• W2401607958 hasConcept C71924100 @default.
• W2401607958 hasConceptScore W2401607958C121608353 @default.
• W2401607958 hasConceptScore W2401607958C126322002 @default.
• W2401607958 hasConceptScore W2401607958C126838900 @default.
• W2401607958 hasConceptScore W2401607958C141071460 @default.
• W2401607958 hasConceptScore W2401607958C143998085 @default.
• W2401607958 hasConceptScore W2401607958C2775842073 @default.
• W2401607958 hasConceptScore W2401607958C2776694085 @default.
• W2401607958 hasConceptScore W2401607958C2777783956 @default.
• W2401607958 hasConceptScore W2401607958C2778019345 @default.
• W2401607958 hasConceptScore W2401607958C2778292576 @default.
• W2401607958 hasConceptScore W2401607958C2778695046 @default.
• W2401607958 hasConceptScore W2401607958C2779013556 @default.
• W2401607958 hasConceptScore W2401607958C2780283643 @default.
• W2401607958 hasConceptScore W2401607958C530470458 @default.
• W2401607958 hasConceptScore W2401607958C71924100 @default.
• W2401607958 hasIssue "InPress" @default.
• W2401607958 hasLocation W24016079581 @default.
• W2401607958 hasLocation W24016079582 @default.
• W2401607958 hasLocation W24016079583 @default.
• W2401607958 hasLocation W24016079584 @default.
• W2401607958 hasOpenAccess W2401607958 @default.
• W2401607958 hasPrimaryLocation W24016079581 @default.
• W2401607958 hasRelatedWork W1255356622 @default.
• W2401607958 hasRelatedWork W2105895425 @default.
• W2401607958 hasRelatedWork W2290126738 @default.
• W2401607958 hasRelatedWork W2358701816 @default.
• W2401607958 hasRelatedWork W2367105124 @default.
• W2401607958 hasRelatedWork W2390548009 @default.
• W2401607958 hasRelatedWork W3032516586 @default.
• W2401607958 hasRelatedWork W3089077900 @default.
• W2401607958 hasRelatedWork W3092055942 @default.
• W2401607958 hasRelatedWork W3205916391 @default.

• next